Optimi Health Establishes Australian Subsidiary

01:11 PM EDT, 10/26/2026 (MT Newswires) -- Optimi Health (OPTI.CN) said on Monday that it established an Australian subsidiary to grow its business in that country. Optimi Australia will be led by Adrian Jones, who was most recently associate director and head of sales and marketing of Bristol Myers Squibb's oncology and cardiovascular portfolios. Optimi Health is a pharmaceutical developer and manufacturer of regulated psychedelic drug products based in the Canadian province British Columbia. The subsidiary will sell Optimi's finished drug products, 5 mg naturally derived psilocybin capsules, and 40 mg and 60 mg MDMA capsules, to clinics and pharmacies under Australia's Authorised Prescriber Scheme. Optimi Health shares were last seen down CA$0.05 at CA$4.45 on the Canadian Securities Exchange. Price: 4.45, Change: -0.05, Percent Change: -1.11